Mile High Labs Welcomes Regulatory Pathway for CBD Products in the UK

Leading cannabinoid extractor supports deadline set by the Food Standards Agency

BROOMFIELD, Colo., Feb. 13, 2020 — Mile High Labs, the world’s leading processor of hemp-derived cannabinoids, today announced its support for the Food Standards Agency’s novel food application process for CBD products in the United Kingdom. Under the requirements, any CBD food products failing to gain regulatory approval before the 31 March 2021 deadline will be taken off the shelves.

“We applaud the FSA for recognizing the demand for CBD in the UK, and for taking the necessary steps to protect consumers,” said Stephen Mueller, Founder and CEO, Mile High Labs. “We are committed to filing our novel foods application and welcome the agency’s progressive focus on CBD compliance.”

A novel food is defined as any food that had not been consumed regularly by humans in the EU before 15 May 1997. Although humans have consumed hemp for much longer, hemp-derived CBD is a relatively new product.

Filing a novel food application requires companies to provide a chemical composition of their product and data that shows it can be manufactured consistently. Additionally, the company must provide safety data to prove that their product is safe for consumption and that it’s stable when formulated into food products.

Mile High Labs has been working on their novel food application for nine months and expects to file later this year.

“There’s a lot of work that goes into this process. It’s not as simple as just filling out a form,” said Wendi Young, VP of Regulatory and Compliance, Mile High Labs. “Typically, it takes around a year to generate the required data and put the information together. Mile High Labs is coming from a position of strength because of our rigorous quality systems.”

Mile High Labs has chosen to file a novel food application specifically for CBD isolate due to isolate’s purity and consistency. The Company anticipates that applicants filing for broad-spectrum products may have a more difficult time meeting the FSA’s requirements due to the variability in the composition of broad-spectrum CBD.

“We urge brands and product manufacturers to ask what their CBD suppliers are doing to prepare for this deadline,” said Christian Hendriksen, VP of International Expansion, Mile High Labs. “As the industry becomes increasingly regulated, it’s more important than ever to partner with a company that understands these requirements and how to meet them.”


Mile High Labs is the global leader in hemp-derived cannabinoid extraction and manufacturing. The company supplies bulk ingredients and private label CBD products to the world’s leading consumer brands. Headquartered in a 400,000-square-foot GMP and ISO 9001 certified production facility in Broomfield, Colorado, Mile High Labs produces cannabinoid-infused tinctures, capsules, tablets, topicals and gummies. In addition to finished products, the company is the largest compliant supplier of cannabinoid isolates, distillates and water soluble formulations.

Want to stay up to date on all things Mile High Labs and the global CBD industry? Opt-in to receive our weekly updates.

    Leave a Reply